Entering New Frontiers in Animal Health

On December 2, Yuyu Venture, a subsidiary of Yuyu Pharma, announced that it has made a strategic investment in Dalan Animal Health, a company contributing to the global food system by developing vaccines for honeybees and shrimp.

Screenshot of Dalan Animal Health homepage. Yuyu Pharmaceutical

Screenshot of Dalan Animal Health homepage. Yuyu Pharmaceutical

View original image

Dalan Animal Health is a US-based biotechnology company developing an innate immunity-based vaccine platform for honeybees and shrimp. The company developed the world’s first insect vaccine (for the prevention of American foulbrood in honeybees), received approval from the United States Department of Agriculture (USDA), and is distributing it in North America. Following the honeybee vaccine, Dalan Animal Health is currently developing a shrimp vaccine that could revolutionize disease management in the aquaculture industry. Founded in 2018, the company is headquartered in Georgia, United States.


This investment was made to play a proactive role in the rapidly growing global animal health industry. Yuyu Venture has assessed Dalan Animal Health’s vaccine platform as a strategically important area for the future of global health and agriculture. Through this investment, Dalan Animal Health plans to expand its research into poultry and other aquaculture species, exploring new applications that can contribute to broad disease prevention in farmed livestock and reduce dependence on antibiotics.


Yoo Wonsang, CEO of Yuyu Pharma, stated, “Key aquaculture species such as bees and shrimp play a vital role in the global food system and environmental stability. This investment reflects our clear commitment to connecting with next-generation technologies in animal health.”


He added, “The animal health sector is becoming a global growth engine, driven by advances in biopharmaceutical technology, the expansion of sustainable aquaculture, and increasing demand for high-quality pet care. Yuyu Venture and Yuyu Pharma will boldly enter new areas of animal health where scientific innovation can create lasting global impact.”



Meanwhile, Yuyu Pharma has designated the animal industry as a next-generation growth engine and is building a portfolio related to the animal industry through strategic investments, encompassing veterinary biologics, sustainable food system technologies, and next-generation pet wellness and community models.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing